SE0002320D0 - Malignant tumors - Google Patents

Malignant tumors

Info

Publication number
SE0002320D0
SE0002320D0 SE0002320A SE0002320A SE0002320D0 SE 0002320 D0 SE0002320 D0 SE 0002320D0 SE 0002320 A SE0002320 A SE 0002320A SE 0002320 A SE0002320 A SE 0002320A SE 0002320 D0 SE0002320 D0 SE 0002320D0
Authority
SE
Sweden
Prior art keywords
malignant tumors
compounds
formula
racemate
tautomer
Prior art date
Application number
SE0002320A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Bjoerk
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0002320A priority Critical patent/SE0002320D0/xx
Publication of SE0002320D0 publication Critical patent/SE0002320D0/xx
Priority to EEP200200207A priority patent/EE200200207A/xx
Priority to ES00973329T priority patent/ES2280258T3/es
Priority to EP00973329A priority patent/EP1224172B1/en
Priority to DK00973329T priority patent/DK1224172T3/da
Priority to KR1020067008739A priority patent/KR100674160B1/ko
Priority to JP2001533112A priority patent/JP3950337B2/ja
Priority to CNB008147574A priority patent/CN100390148C/zh
Priority to YUP-232/02A priority patent/RS51019B/sr
Priority to UA2002032524A priority patent/UA73748C2/uk
Priority to AU11851/01A priority patent/AU775057B2/en
Priority to DE60034240T priority patent/DE60034240T2/de
Priority to HU0203238A priority patent/HU229072B1/hu
Priority to NZ518296A priority patent/NZ518296A/xx
Priority to KR1020027005077A priority patent/KR100597938B1/ko
Priority to IL14878200A priority patent/IL148782A0/xx
Priority to US09/694,757 priority patent/US6395750B1/en
Priority to CZ20021293A priority patent/CZ298534B6/cs
Priority to CA002386775A priority patent/CA2386775C/en
Priority to PCT/SE2000/002055 priority patent/WO2001030758A1/en
Priority to PL354540A priority patent/PL199781B1/pl
Priority to AT00973329T priority patent/ATE358668T1/de
Priority to IL148782A priority patent/IL148782A/en
Priority to IS6329A priority patent/IS2750B/is
Priority to HR20020353A priority patent/HRP20020353A2/hr
Priority to NO20021932A priority patent/NO323320B1/no
Priority to HK03100644.7A priority patent/HK1049830A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0002320A 1999-10-25 2000-06-21 Malignant tumors SE0002320D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PL354540A PL199781B1 (pl) 1999-10-25 2000-10-24 Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
AT00973329T ATE358668T1 (de) 1999-10-25 2000-10-24 Drogen zur behandlung maligner tumoren
DE60034240T DE60034240T2 (de) 1999-10-25 2000-10-24 Drogen zur behandlung maligner tumoren
KR1020027005077A KR100597938B1 (ko) 1999-10-25 2000-10-24 악성 종양의 치료용 약제
EP00973329A EP1224172B1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
DK00973329T DK1224172T3 (da) 1999-10-25 2000-10-24 Medikamenter til behandling af ondartede tumorer
KR1020067008739A KR100674160B1 (ko) 1999-10-25 2000-10-24 악성 종양의 치료용 약제
JP2001533112A JP3950337B2 (ja) 1999-10-25 2000-10-24 悪性腫瘍治療薬
CNB008147574A CN100390148C (zh) 1999-10-25 2000-10-24 用于治疗恶性肿瘤的药物
YUP-232/02A RS51019B (sr) 1999-10-25 2000-10-24 Lekovi za lečenje malignih tumora
UA2002032524A UA73748C2 (en) 1999-10-25 2000-10-24 Medicaments for the treatment of cancer
AU11851/01A AU775057B2 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
EEP200200207A EE200200207A (et) 1999-10-25 2000-10-24 Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid
HU0203238A HU229072B1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
NZ518296A NZ518296A (en) 1999-10-25 2000-10-24 N-phenyl-1,2-dihydro-2-oxo-quinoline-3-carboxamide derivatives and their use in the treatment of breast and prostatic cancer
ES00973329T ES2280258T3 (es) 1999-10-25 2000-10-24 Farmacos para el tratamiento de tumores malignos.
IL14878200A IL148782A0 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
US09/694,757 US6395750B1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumors
CZ20021293A CZ298534B6 (cs) 1999-10-25 2000-10-24 Lécivo k lécbe maligních nádoru
CA002386775A CA2386775C (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
IL148782A IL148782A (en) 1999-10-25 2002-03-20 Drugs for the treatment of malignant tissues
IS6329A IS2750B (is) 1999-10-25 2002-04-02 Leiðarafesting
HR20020353A HRP20020353A2 (en) 1999-10-25 2002-04-23 Drugs for the treatment of malignant tumours
NO20021932A NO323320B1 (no) 1999-10-25 2002-04-24 Medikament egnet til behandling av ondartede tumorer
HK03100644.7A HK1049830A1 (zh) 1999-10-25 2003-01-24 用於治療惡性腫瘤的藥物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours

Publications (1)

Publication Number Publication Date
SE0002320D0 true SE0002320D0 (sv) 2000-06-21

Family

ID=27484521

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors

Country Status (21)

Country Link
EP (1) EP1224172B1 (uk)
JP (1) JP3950337B2 (uk)
KR (2) KR100674160B1 (uk)
AT (1) ATE358668T1 (uk)
AU (1) AU775057B2 (uk)
CA (1) CA2386775C (uk)
CZ (1) CZ298534B6 (uk)
DE (1) DE60034240T2 (uk)
DK (1) DK1224172T3 (uk)
EE (1) EE200200207A (uk)
ES (1) ES2280258T3 (uk)
HK (1) HK1049830A1 (uk)
HR (1) HRP20020353A2 (uk)
HU (1) HU229072B1 (uk)
IL (2) IL148782A0 (uk)
IS (1) IS2750B (uk)
NO (1) NO323320B1 (uk)
NZ (1) NZ518296A (uk)
SE (1) SE0002320D0 (uk)
UA (1) UA73748C2 (uk)
WO (1) WO2001030758A1 (uk)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
ES2656017T3 (es) 2004-06-24 2018-02-22 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
JP5832716B2 (ja) 2005-10-19 2015-12-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶，及びその製造方法
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
SI2035001T1 (sl) 2006-06-12 2012-03-30 Teva Pharma Stabilni pripravki lakvinimoda
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
NZ591315A (en) 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
MX2013004169A (es) 2010-10-14 2013-06-05 Immunahr Ab 1, 2-dihidro-4-hidroxi-2-oxo-quinolina-3-carboxanilidas como activadores del receptor de hidrocarburo aromatico.
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
AU2013226076B2 (en) 2012-02-27 2017-11-16 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
EP2916915A4 (en) * 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
CN107108510B (zh) 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
CN107072989B (zh) 2014-11-19 2020-07-03 活跃生物技术有限公司 用于治疗白血病的喹啉甲酰胺
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
KR20220149579A (ko) 2020-03-03 2022-11-08 액티브 바이오테크 에이비 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
US20230203003A1 (en) * 2020-05-21 2023-06-29 Stemsynergy Therapeutics, Inc. Notch Inhibitors and Uses Thereof
KR20230133317A (ko) 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
CN117295492A (zh) 2021-05-25 2023-12-26 活跃生物技术有限公司 多个他喹莫德粒子及其用途
EP4363404A1 (en) 2021-07-02 2024-05-08 Active Biotech AB A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
TWI838849B (zh) * 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
JP3950337B2 (ja) 2007-08-01
ES2280258T3 (es) 2007-09-16
EE200200207A (et) 2003-06-16
KR20020043646A (ko) 2002-06-10
CZ20021293A3 (cs) 2002-07-17
HU229072B1 (en) 2013-07-29
DE60034240D1 (de) 2007-05-16
JP2003512454A (ja) 2003-04-02
IS6329A (is) 2002-04-02
IL148782A (en) 2007-05-15
CA2386775C (en) 2004-07-13
IL148782A0 (en) 2002-09-12
HUP0203238A3 (en) 2003-05-28
HUP0203238A2 (hu) 2003-01-28
CA2386775A1 (en) 2001-05-03
ATE358668T1 (de) 2007-04-15
DK1224172T3 (da) 2007-08-13
HRP20020353A2 (en) 2005-10-31
DE60034240T2 (de) 2007-12-20
WO2001030758A1 (en) 2001-05-03
NO20021932D0 (no) 2002-04-24
CZ298534B6 (cs) 2007-10-31
NO20021932L (no) 2002-06-21
UA73748C2 (en) 2005-09-15
AU775057B2 (en) 2004-07-15
KR100597938B1 (ko) 2006-07-06
KR100674160B1 (ko) 2007-01-24
EP1224172A1 (en) 2002-07-24
HK1049830A1 (zh) 2003-05-30
KR20060054496A (ko) 2006-05-22
IS2750B (is) 2011-08-15
NO323320B1 (no) 2007-03-12
AU1185101A (en) 2001-05-08
NZ518296A (en) 2003-06-30
EP1224172B1 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
SE0002320D0 (sv) Malignant tumors
YU23202A (sh) Lekovi za tretman malignih tumora
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
SE9904505D0 (sv) Novel compounds
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
SE0104140D0 (sv) Novel Compounds
GB0112348D0 (en) Compounds
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
SE0103836D0 (sv) Novel compounds
ATE316083T1 (de) Adamantanderivate
EA200101046A1 (ru) Производные индигоидных бис-индолов
SE9901875D0 (sv) Novel compounds
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
ATE233754T1 (de) Diphenyl-piperidin derivate
ATE238981T1 (de) Antitumorwirkstoffe
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
MXPA04005809A (es) Inhibidores de proteinas quinasas.
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
CY1106576T1 (el) Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας
BR0116123A (pt) Carbazóis antitumorais
NO20030420D0 (no) Medikament for immunoterapi av maligne tumorer
SE0004827D0 (sv) Therapeutic compounds
WO2002098399A3 (en) Cancer treatment method and compositions comprising compounds of the ginger family